Testing AK127 plus AK104 for advanced cancers
Part of Cancer clinical trials.
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and able to give written informed consent.
- Your cancer must be advanced, recurrent, or metastatic, confirmed by lab tests (tumor tissue or cells).
- Your body’s overall function should be good (ECOG performance status 0 or 1) and you should have at least 3 months expected survival.
- You must have at least one measurable tumor spot that can be measured again over time; brain metastases cannot be used as the measuring target.
- You must have blood work/organ function that the study considers “good enough” for treatment (your clinicians will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial tests a new drug called AK-1286 for people with advanced solid tumors who have not responded to or could not tolerate standard treatments. The goal is to see how safe and effective the drug is.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.